GRANISETRON HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H24N4O.ClH
Molecular Weight	348.87
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=CC=CC=C14

InChI

InChIKey=QYZRTBKYBJRGJB-WQTKJZBYSA-N

InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H/t12-,13+,14-;

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H24N4O
Molecular Weight	312.4094
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00889
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf

Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting. Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone. Granisetron is used for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 3a (5-HT3a) receptor 46 Target ID: CHEMBL1899 Sources: http://www.drugbank.ca/drugs/DB00889	Antagonist 2778		1.45 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nausea and vomiting associated with emetogenic chemotherapy 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf	Secondary		Approved 8429	SUSTOL Approved Use SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Launch Date 1992

C_max

Value	Dose	Co-administered	Analyte	Population
4.948 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22452942	10 μg/kg bw single, intravenous dose: 10 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		GRANISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
36.87 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22452942	10 μg/kg bw single, intravenous dose: 10 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		GRANISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22452942	10 μg/kg bw single, intravenous dose: 10 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		GRANISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 mg 2 times / day multiple, oral Highest studied dose Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7758060/	unhealthy, 50.6 years (range: 23-76 years) n = 233 Health Status: unhealthy Condition: nausea and vomiting, chemotherapy-Induced Age Group: 50.6 years (range: 23-76 years) Sex: M+F Population Size: 233 Sources: https://pubmed.ncbi.nlm.nih.gov/7758060/	Other AEs: Constipation, Headache... Other AEs: Constipation (27.5%) Headache (17.6%) Leukopenia (15%) Asthenia (6.9%) Abdominal pain (9%) Decreased appetite (5.6%) Anemia (1.3%) Diarrhea (4.3%) Abnormal liver function tests (2.6%) Alopecia (3%) Pain (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/7758060/
160 ug/kg single, intravenous Highest studied dose Dose: 160 ug/kg Route: intravenous Route: single Dose: 160 ug/kg Co-administed with:: cisplatin(>50 mg/m^2) Sources: https://pubmed.ncbi.nlm.nih.gov/8032704/	unhealthy, 54 n = 165 Health Status: unhealthy Condition: nausea and vomiting, chemotherapy-Induced Age Group: 54 Sex: M+F Population Size: 165 Sources: https://pubmed.ncbi.nlm.nih.gov/8032704/	Other AEs: Headache, Constipation... Other AEs: Headache (13.9%) Constipation (4.2%) Somnolence (2.4%) Dizziness (1.2%) Dyspepsia (1.8%) Back pain (3%) Sources: https://pubmed.ncbi.nlm.nih.gov/8032704/
15 mg single, subcutaneous Highest studied dose Dose: 15 mg Route: subcutaneous Route: single Dose: 15 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25834466/	unhealthy, 64.3 n = 13 Health Status: unhealthy Condition: nausea and vomiting, chemotherapy-Induced Age Group: 64.3 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/25834466/	Other AEs: Constipation, Diarrhea... Other AEs: Constipation (23.1%) Diarrhea (15.4%) Headache (30.8%) Fatigue (15.4%) Anorexia (15.4%) Weight loss (7.7%) Dizziness (7.7%) Neutropenia (15.4%) Mucosal inflammation (15.4%) Dyspnea (7.7%) Insomnia (7.7%) Thrombocytopenia (7.7%) Injection site bruising (7.7%) Pain injection site (2.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/25834466/
1 mg single, intravenous Recommended Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf	unhealthy n = 267 Health Status: unhealthy Condition: nausea and vomiting, postoperative Population Size: 267 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf	Other AEs: Pain, Constipation... Other AEs: Pain (10.1%) Constipation (9.4%) Anemia (9.4%) Headache (8.6%) Fever (7.9%) Abdominal pain (6%) Hepatic enzymes increased (5.6%) Insomnia (4.9%) Bradycardia (4.5%) Dizziness (4.1%) Leukocytosis (3.7%) Anxiety (3.4%) Hypotension (3.4%) Diarrhea (3.4%) Flatulence (3%) Infection (3%) Dyspepsia (3%) Hypertension (2.6%) Urinary tract infection (2.6%) Oliguria (2.2%) Coughing (2.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf
40 ug/kg single, intravenous Recommended Dose: 40 ug/kg Route: intravenous Route: single Dose: 40 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf	unhealthy n = 1268 Health Status: unhealthy Condition: nausea and vomiting, chemotherapy-Induced Population Size: 1268 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf	Other AEs: Headache, Asthenia... Other AEs: Headache (14%) Asthenia (5%) Somnolence (4%) Diarrhea (4%) Constipation (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A1 349 CYP1A2 1054 CYP1B1 92 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2C19 991 CYP2E1 667 CYP2J2 56 CYP3A5 395 CYP3A7 110

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP1B1 92	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP2J2 56	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP3A7 110	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	likely
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=113; https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf#page=12 Page: 113.0	major	unknown (co-administration study) Comment: Administration of intravenous granisetron hydrochloride with phenobarbital, an enzyme inducer, resulted in a 25% increase in total plasma clearance of granisetron. The clinical significance of this interaction is not known. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=113; https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf#page=12 Page: 113.0
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=113; https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf#jpage=12 Page: 113.0	minor	unknown (co-administration study) Comment: the potential for an in vivo pharmacokinetic interaction with ketoconazole is not known; Administration of intravenous granisetron hydrochloride with phenobarbital, an enzyme inducer, resulted in a 25% increase in total plasma clearance of granisetron. The clinical significance of this interaction is not known. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=113; https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf#jpage=12 Page: 113.0
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	no
CYP2C18 138	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	no
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	no
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022445Orig1s000ClinPharmR.pdf#page=108 Page: 108.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/11046096/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5537	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5537
ChemicalBook	CB2728852	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2728852
ZINC	ZINC000100018854	http://zinc15.docking.org/substances/ZINC000100018854
eMolecules	32452667	https://www.emolecules.com/cgi-bin/more?vid=32452667

PubMed

Title	Date	PubMed
The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.	2001	11824878
The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy.	2001	11768028
Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.	2001	11760147
[Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy].	2001 Apr	11411097
5-HT1A and 5-HT2 receptors differentially regulate the excitability of 5-HT-containing neurones of the guinea pig dorsal raphe nucleus in vitro.	2001 Apr 27	11311877
[Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].	2001 Aug 5	11556262
IgE-mediated allergy to granisetron and safe use of ondansetron.	2001 Dec	11742289
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.	2001 Dec	11720834
The influence of a dominating centre on a quantitative systematic review of granisetron for preventing postoperative nausea and vomiting.	2001 Jul	11421822
A placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction.	2001 Jun	11465525
Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting.	2001 Jun	11440292
Pegylated liposomal doxorubicin: tolerability and toxicity.	2001 Jun	11401188
Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in children.	2001 Jun	11371485
Binding characteristics of GYKI-46 903, a non-competitive ligand at 5-HT3 receptors.	2001 Mar	11401422
Preoperative oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery.	2001 Mar	11316402
5-Hydroxytryptamine (5-HT)-induced depolarization in isolated abdominal vagus nerves in the rat: involvement of 5-HT3 and 5-HT4 receptors.	2001 Mar-Apr	11758651
Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport.	2001 May	11393584
Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study.	2001 Nov	11762972
Barostat examination of proximal site of the anastomosis in patients with rectal cancer after low anterior resection.	2001 Nov	11760737
Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.	2001 Nov	11704657
5-HT receptor subtypes involved in the spinal antinociceptive effect of acetaminophen in rats.	2001 Nov 30	11734181
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.	2001 Oct 19	11710819
Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors.	2001 Oct 5	11675038
Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.	2001 Sep	11554235
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?	2002	11854548
5-Hydroxytryptamine receptors, especially the 5-HT4 receptor, in guinea pig urinary bladder.	2002 Aug	12233812
Progress in preventing chemotherapy-induced nausea and vomiting.	2002 Aug	12184469
Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways.	2002 Aug	12121888
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.	2002 Aug 12	12177775
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.	2002 Feb 1	11875692
Emerging treatments for irritable bowel syndrome.	2002 Jan	11772329
Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery.	2002 Jul	12167446
Laxative and anti-diarrheal activity of polycarbophil in mice and rats.	2002 Jun	12120755
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.	2002 Jun	12051870
Identification of critical residues in loop E in the 5-HT3ASR binding site.	2002 Jun 13	12079500
Preoperative oral granisetron for the prevention of vomiting following paediatric surgery.	2002 Mar	11903942
Clinical evaluation of granisetron as an inhibitor of nausea and vomiting induced by oral anticancer drugs.	2002 Mar-Apr	11836592
Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron.	2002 May-Jun	12166338
Oral granisetron revisited.	2002 Nov	12519146
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.	2002 Nov 4	12402144
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.	2002 Oct 7	12373598
[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].	2002 Sep	12485511
In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytryptamine4 receptor in dog intestine.	2002 Sep	12396025
Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer.	2003	12457031
Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron.	2003 Feb	12588407
Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia.	2003 Feb	12583870
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.	2003 Feb	12562658
Granisetron: relating pharmacology to clinical efficacy.	2003 Feb	12560937
Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.	2003 Jan	12568305
Pharmacological characterization of the 5-HT1A, 5-HT2 and 5-HT3 receptors in the bovine ciliary muscle.	2003 Mar 7	12600697

Patents

Sample Use Guides

In Vivo Use Guide

IV: 10 mcg/kg over 5 minutes, beginning 30 minutes before initiation of chemotherapy. Orally: 2 mg, given up to 1 hour before chemotherapy, or 1 mg twice a day (the first dose is given up to 1 hour before chemotherapy, and the second dose is given 12 hours later). Granisetron transdermal system: Apply a single patch to the upper outer arm a minimum of 24 hours before chemotherapy. The patch may be applied up to a maximum of 48 hours before chemotherapy as appropriate. Remove the patch a minimum of 24 hours after completion of chemotherapy. The patch can be worn for up to 7 days depending on the duration of the chemotherapy regimen. Granisetron transdermal system is a 52 cm2 patch containing 34.3 mg of granisetron. The patch releases 3.1 mg of granisetron per 24 hours for up to 7 days.

Route of Administration: Other

In Vitro Use Guide

Granisetron (1 uM) shifted the response curves to mucosally applied 5-HT to the right in a parallel and surmountable manner in the guinea pig isolated ileum.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:51:24 GMT 2023` Edited by `admin` on `Fri Dec 15 15:51:24 GMT 2023`
Record UNII	318F6L70J8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GRANISETRON HYDROCHLORIDE

Official Name

English

GRANISETRON HYDROCHLORIDE [MI]

Common Name

English

NSC-759839

Code

English

GRANISETRON HYDROCHLORIDE [JAN]

Common Name

English

GRANISETRON HYDROCHLORIDE [USAN]

Common Name

English

GRANISETRON HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

GRANISETRON (AS HYDROCHLORIDE)

Common Name

English

GRANISETRON HYDROCHLORIDE [MART.]

Common Name

English

GRANISETRON HYDROCHLORIDE [USP-RS]

Common Name

English

GRANISETRON HYDROCHLORIDE [VANDF]

Common Name

English

BRL 43694A

Code

English

GRANISETRON HYDROCHLORIDE [USP IMPURITY]

Common Name

English

BEMA GRANISETRON

Brand Name

English

1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-, MONOHYDROCHLORIDE, ENDO-

Common Name

English

Granisetron hydrochloride [WHO-DD]

Common Name

English

1-METHYL-N-(9-METHYL-ENDO-9-AZABICYCLO(3.3.1)NON-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE MONOHYDROCHLORIDE

Common Name

English

GRANISETRON HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

GRANISETRON HCL

Common Name

English

GRANISETRON HYDROCHLORIDE [EP IMPURITY]

Common Name

English

GRANISETRON HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

KYTRIL

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C267